Moclobemide treatment in multiple sclerosis patients with comorbid depression: An open-label safety trial

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 11, Issue 2, 1999, Pages 271-273

  Barak, Yoram ^a,b   Ur, Erel ^a   Achiron, Anat ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MALE; MULTIPLE SCLEROSIS; NAUSEA; PRIORITY JOURNAL; REMISSION;

EID: 0032958929     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.11.2.271     Document Type: Article

References (16)

1. Minden SL, Schiffer RB: Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol 1990; 47:98-104
2. Sadovnik AD, Eisen K, Ebers GC, et al: Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193-1196
3. Sadovnik AD, Remick RA, Allen J, et al: Depression and multiple sclerosis. Neurology 1996; 46:628-632
4. Mahler ME: Behavioral manifestations associated with multiple sclerosis. Psychiatr Clin North Am 1992; 15:427-438
5. Schiffer RB, Wineman MN: Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 17:1493-1497
6. Silver JM, Hales RE, Yudofsky SC: Psychopharmacology of depression in neurologic disorders. J Clin Psychiatry 1990; 51:33-39
7. Kwan SW, Bergeron JM, Abell CW: Molecular properties of monoamine oxidases A and B. Psychopharmacol 1992; 106:1-5
8. Nair NPV, Ahmed SK, Ng-Ying Kin NMK, et al: Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand 1995; 91:28-35
9. Ramaekers JG, Swijgman HF, O'Hanlon JF: The effect of moclobemide and mianserine on highway driving, psychometric performances and subjective parameters: relation to placebo. Psychopharmacology 1992; 106:562-567
10. Beck AT: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
11. Noy S, Achiron A, Gabbay U, et al: A new approach to affective symptoms in relapsing-remitting multiple sclerosis. Compr Psychiatry 1995; 36:1-7
12. Baber N: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Br J Clin Pharmacol 1994; 37:401-404
13. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231
14. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452
15. Scott TF, Nussbaum P, McConnell H, et al: Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995; 17:421-422
16. Barak Y, Kimhi R, Bodner E, et al: Treatment of depression in patients with multiple sclerosis. The Neurologist 1998; 4:99-104